These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22536025)

  • 1. Ustekinumab biotherapy and real-time psoriasis capacitance mapping: a pilot study.
    Piérard-Franchimont C; Piérard GE
    J Biomed Biotechnol; 2012; 2012():870194. PubMed ID: 22536025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 8. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease.
    Hermanns-Lê T; Berardesca E; Piérard GE; Lesuisse M; Piérard-Franchimont C
    J Biomed Biotechnol; 2012; 2012():413767. PubMed ID: 22927720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin capacitance mapping of psoriasis.
    Xhauflaire-Uhoda E; Piérard-Franchimont C; Piérard GE
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1261-5. PubMed ID: 17062043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
    Assefa GT; Kaneko S; Oguro H; Morita E
    J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to Secukinumab after Treatment Failure with Ustekinumab in 6 Patients with Plaque Psoriasis.
    Morgado-Carrasco D; Riera-Monroig J; Fustà-Novell X; Alsina Gibert M
    Actas Dermosifiliogr (Engl Ed); 2018; 109(6):565-567. PubMed ID: 29169562
    [No Abstract]   [Full Text] [Related]  

  • 18. Ustekinumab in the treatment of severe rupioid psoriasis: A case report.
    Necas M; Vasků V
    Acta Dermatovenerol Alp Pannonica Adriat; 2010; 19(2):23-7. PubMed ID: 20664917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G; Errichetti E
    BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.